Physician profile
Kate Sugden
NPI 1225894835
$2,935.97
in general payments reported to CMS, 2019-2025
18 companies · $2,339 in 2025
The $2,339 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $597 · 2025: $2,339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,936.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,935.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,084.89 | 2024-2025 | |
| Janssen Biotech, INC. | $480.40 | 2025 | Tremfya |
| Lilly USA, LLC | $279.56 | 2024-2025 | Omvoh |
| Takeda Pharmaceuticals U.S.A., INC. | $217.13 | 2024-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $188.01 | 2025 | Xifaxan |
| Aimmune Therapeutics, INC. | $116.14 | 2024-2025 | Zenpep |
| Pfizer INC. | $95.89 | 2025 | |
| Ardelyx, INC. | $81.78 | 2024-2025 | Ibsrela |
| Celltrion USA INC. | $77.56 | 2024-2025 | Vegzelma |
| Madrigal Pharmaceuticals | $69.19 | 2024-2025 | Rezdiffra, Resmetirom |
| Braintree Laboratories, INC. | $54.02 | 2025 | Sutab, Suflave |
| Genzyme Corporation | $44.75 | 2025 | |
| Qol Medical, LLC | $38.79 | 2025 | Sucraid |
| Novo Nordisk INC | $36.53 | 2025 | Wegovy |
| Merck Sharp & Dohme LLC | $22.75 | 2024 | Dificid |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $20.88 | 2025 | Iqirvo |
| Regeneron Healthcare Solutions, INC. | $16.67 | 2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $11.03 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kate Sugden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.